Navigation Links
NUCRYST Receives Deficiency Notice from NASDAQ
Date:8/15/2008

WAKEFIELD, MA, Aug. 15 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on August 14, 2008, it received notice from The Nasdaq Stock Market stating that, for the last 30 consecutive trading days, the Company's common shares had not maintained the minimum market value of publicly held shares ("MVPHS") of $5 million required for continued listing on The Nasdaq Global Market under Marketplace Rule 4450(a)(2) (the "Rule"). Receipt of this notice has no immediate effect on the listing of the Company's common shares. The Company has 90 calendar days, or until November 12, 2008, to regain compliance with the Rule.

The notice states that if at any time before November 12, 2008, the MVPHS of NUCRYST's common shares is $5 million or more for a minimum of 10 consecutive trading days, Nasdaq will provide written notification that the Company complies with the Rule. If the Company cannot demonstrate compliance with that Rule by November 12, 2008, Nasdaq staff will notify the Company that its securities will be delisted from The Nasdaq Global Market. If the Company receives a delisting notice, the Nasdaq Marketplace Rules would permit the Company to appeal the Nasdaq staff's determination to delist its securities to a Nasdaq Listing Qualifications Panel.

NUCRYST is currently evaluating its alternatives to resolve the listing deficiency. If the Company is unable to resolve the listing deficiency, it may apply to transfer its common shares to The Nasdaq Capital Market. In order to transfer, the Company must satisfy the continued inclusion requirements for that market which the Company believes it currently does. If the Company submits a transfer application by November 12, 2008, the initiation of the delisting proceedings will be stayed pending the Nasdaq staff's review of the application.

About NUCRYST Pharmaceuticals

NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by pain, infection and inflammation. The Company has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101 for use in medical devices and as an active pharmaceutical ingredient.

Acticoat(TM) is a trademark of Smith & Nephew plc

SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

This news release contains forward-looking statements within the meaning of securities legislation in the United States and Canada (collectively "forward-looking statements"). The words "believes", "expects", "plans", "anticipates", "estimates", "intends", "projects", "may", "might", "would", "will", "could", "should" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this news release include, but are not limited to, statements about: the future plans of our management in relation to resolving our exchange listing deficiency. With respect to the forward-looking statements contained in this news release, readers are cautioned that numerous risks, uncertainties and other factors could cause our actual results to differ materially from those indicated in these statements including, but not limited to risks associated with: the performance of stock markets generally; our ability to satisfy regulatory and stock exchange standards and requirements to maintain our exchange listing; our ability to maintain our collaboration with Smith & Nephew; our reliance on sales of Acticoat(TM) products with our SILCRYST(TM) coatings by Smith & Nephew; the impact of competitive products and pricing on sales of Acticoat(TM) products with our SILCRYST(TM) coatings by Smith & Nephew; our ability to retain existing and obtain new regulatory approvals for any future products; the extent to which we are able to develop and gain market acceptance of new products; and our ability to establish successful commercialization programs, through new corporate collaborations or otherwise. Although we have attempted to identify the important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in forward looking statements. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our Annual Report on Form 10-K for the year ended December 31, 2007 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed with the U.S. Securities and Exchange Commission on EDGAR at http://www.sec.gov and with securities authorities in Canada on SEDAR at http://www.sedar.com. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and NUCRYST disclaims any intention or obligation to revise or update any forward-looking statements whether as a result of new information, future developments or otherwise after the date hereof.


'/>"/>
SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NUCRYST and Smith & Nephew Revise Agreements
2. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. NUCRYST Pharmaceuticals announces 2007 third quarter results
4. NUCRYST Pharmaceuticals announces year-end results
5. NUCRYST Announces Senior Management Change
6. NUCRYST Announces Management Realignment and R&D Portfolio Change
7. NUCRYST Announces First Quarter 2008 Financial Results
8. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
9. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
10. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
11. DaVita Receives Civil Complaint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social Media: ... journal chronicling the writer’s path toward true communion with God. “Finding Christ Through ... is the creation of published author Lea Michelle Johnson, a follower of Christ, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “Vintage and ... a retired minister and college Bible teacher residing in North Carolina with his wife, ... who have blessed them with six grandchildren. David is also the author of “Shadow ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story ... fullest, as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” ... passion for writing, especially about truth and human behavior. , Published by Christian Faith ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates for ... on a review of GPA and SAT/ACT requirements at 221 institutions in 25 states, ... that this higher bar should be set by states, by the Council for the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $3.5 ... estimates and forecasts for all the given segments on global as ...
(Date:3/23/2017)... , March 23, 2017 The ... ageing population, increasing diabetic population, accelerating economic growth and increasing ... this industry are higher life expectancy of ESRD patients, rising ... emerging markets. However, the expansion of the market is hindered ... ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a multi-modal ... end-to-end supply chain management firm with expertise serving clients ... Solutions Rick Zaffarano was named a 2017 ... Supply Chain by the only publication exclusively dedicated to ... supply chain. "Rick has brought to Transportation ...
Breaking Medicine Technology: